SP Tulsian, sptulsian.com is positive on Cox & Kings .
Tulsian told CNBC-TV18, "Cox and Kings, I have my positive view. In fact if you see yesterday also it moved up and today also it has moved up. But on Jubilant Foods I am maintaining my negative view. In fact still I see the stock grossly overvalued. Wherever we see any kind of upside coming in, it is more of a trading nature. On a pure fundamental basis I still consider the stock as grossly overvalued."
He further added, "Lipitor, I don't think that the kind of benefits which we were expecting from Ranbaxy to happen has really seen happening because firstly I think the market has mistaken in calculating the kind of profits that they can make and all sort of things because generally on the generic version the margins fall as high as 75-80%, number one. Number two; there is no direct marketing arrangement by Ranbaxy because again it has been down via. So I don't think that all these things have really cheered the markets. Overall that was seen to be a big disappointment."
